

Form PTO-1449 (modified)

Atty. Docket No.:

CLFR:029USD1

Serial No.:

10/676,725

List of Patents and Publications for Applicant's

Applicant:

Michael ROSENBLUM

Filing Date:

October 1, 2003

Group:

1642

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Patent Documents

See Page 1

Foreign Patent Documents

See Page 1-2

Other Art

See Page 2-3

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A50	2005/0214307	09/29/05	Rosenblum <i>et al.</i>	424	178.1	08/26/04
	A51	2002/0090374	07/11/02	Yarkoni <i>et al.</i>	724	178.1	03/02/98
	A52	5,621,083	04/15/97	Better <i>et al.</i>	530	391.9	04/18/95
	A53	5,830,880	11/03/98	Sedlacek <i>et al.</i>	514	44	04/18/97
	A54	5,851,829	12/22/98	Marasco <i>et al.</i>	435	328	03/30/95
	A55	6,140,066	10/31/00	Lorberboum-Galski <i>et al.</i>	435	7.23	03/24/98
	A56	6,197,528	03/06/01	Wu <i>et al.</i>	435	7.2	02/12/99
	A57	6,218,165	04/17/01	Estell <i>et al.</i>	435	221	02/23/99
	A58	6,309,873	10/30/01	Torrens Madrazo <i>et al.</i>	435	216	08/13/99
	A59	6,531,133	03/11/03	Lorberboum-Galski <i>et al.</i>	424	197.11	01/27/99
	A60	6,639,054	10/28/03	Alibhai <i>et al.</i>	530	350	01/05/01
	A61	6,703,020	03/09/04	Thorpe <i>et al.</i>	424	178.1	04/28/00
	A62	7,083,957	08/01/06	Rosenblum <i>et al.</i>	435	183	02/12/02

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B44	EP 0893493	01/27/99	Europe	German (English Abstract)
	B45	WO 00/26406	05/11/00	WIPO	English
	B46	WO 00/42179	07/20/00	WIPO	German (English Abstract)
	B47	WO 02/074979	09/26/02	WIPO	English
	B48	WO 02/42420	05/30/02	WIPO	English
	B49	WO 90/013649	11/15/90	WIPO	English
	B50	WO 98/37901	09/03/98	WIPO	English

25761645.1

EXAMINER:

/Laura B. Goddard/

DATE CONSIDERED:

04/24/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.B.G./

Form PTO-1449 (modified)		Atty. Docket No.: CLFR:029USD1	Serial No.: 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT		Applicant: Michael ROSENBLUM	
(Use several sheets if necessary)		Filing Date: October 1, 2003	Group: 1642
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-3</i>	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B51	WO 99/29721	06/17/99	WIPO	English
	B52	WO 99/43840	09/02/99	WIPO	English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C186	Ardekani <i>et al.</i> , "Molecular profiling of cancer and drug-induced toxicity using new proteomic technologies," <i>Current Therapeutic Res.</i> , 62:803-819, 2001.
	C187	Arora, "Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells," <i>Cancer Research</i> , 59:183-188, 1999.
	C188	Better <i>et al.</i> , "Gelonin analogs with engineered cysteine residues form antibody immunoconjugates with unique properties," <i>J. Biol. Chem.</i> , 269:9644-9650, 1994.
	C189	Clarke <i>et al.</i> , "Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential," <i>Biochemical Pharmacology</i> , 62:1311-1336, 2001.
	C190	Fischer <i>et al.</i> , "Difluoromethylornithine is effective as both a preventive and therapeutic agent against the development of UV carcinogenesis in SKH hairless mice," <i>Carcinogenesis</i> , 22(1):83-88, 2001.
	C191	Fitzgerald <i>et al.</i> , "Why toxins!," <i>Seminars in Cancer Biology</i> , 7:87-95, 1996.
	C192	Hamawy <i>et al.</i> , "Activation of T lymphocytes for adhesion and cytokine expression by toxin-conjugated anti-CD3 monoclonal antibodies," <i>Transplantation</i> , 68:693-698, 1999.
	C193	Ivanov, "Therapeutic monoclonal antibodies in oncology," <i>Medicinal Immunol.</i> , 3:268, 2001.
	C194	Johnson <i>et al.</i> , "Construction of an epitope vector utilizing the diphtheria toxin B-subunit," <i>FEMS Microbiol. Lett.</i> , 146:91-96, 1997.
	C195	Liu <i>et al.</i> , "Mechanistic studies of a novel, human fusion toxin composed of vascular endothelial growth factor (VEGF) ₁₂₁ and the serine protease granzyme B: Directed apoptotic events in vascular endothelial cells," <i>Molecular Cancer Therapeutics</i> , 2:949-959, 2003.

25761645.1

EXAMINER:

/Laura B. Goddard/

DATE CONSIDERED:

04/24/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.B.G./

Form PTO-1449 (modified)		Atty. Docket No.: CLFR:029USD1	Serial No.: 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT		Applicant: Michael ROSENBLUM	
(Use several sheets if necessary)		Filing Date: October 1, 2003	Group: 1642
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-3</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C196	Liu <i>et al.</i> , "Targeted delivery of human pro-apoptotic enzymes to tumor cells: In vitro studies describing a novel class of recombinant highly cytotoxic agents," <i>Mol. Cancer Ther.</i> , 2:1341-1350, 2003
	C197	McGraw <i>et al.</i> , "Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias," <i>Cancer Immunol. Immunother.</i> , 39:367-374, 1994.
	C198	Murray <i>et al.</i> , "Radioimmunoimaging in Malignant Melanoma Patients With the Use of Indium-111-labeled Antimelanoma Monoclonal Antibody (ZME-018) to High-molecular-weight Antigen," <i>NCI Monogr.</i> , 3:3-9, 1987.
	C199	Parakh <i>et al.</i> , "Cloning a single-chain analogue of the anti-melanoma monoclonal antibody ZME-018: Construction and testing of an antibody recombinant gelonin fusion toxin," <i>Proc. Am. Assoc. Cancer Res. Annual Meetings</i> , 36:488, 1995 (Abstract 2909).
	C200	Roscoe <i>et al.</i> , "Primate antibody response to immunotoxin: serological and computer-aided analysis of epitopes on a truncated form of <i>Pseudomonas</i> exotoxin," <i>Infect. Immun.</i> , 62:5055-5065, 1994.
	C201	Rosenblum <i>et al.</i> , "Cellular resistance to the antimelanoma immunotoxin ZME-gelonin and strategies to target resistant cells," <i>Cancer Immunol. Immunother.</i> , 42:115-121, 1996.
	C202	Sairam <i>et al.</i> , "Structural characterization of gelonin: evidence for separate antigenic and cytotoxic domains," <i>Biochemistry and Molecular Biology International</i> , 31:575-581, 1993.
	C203	Shoemaker <i>et al.</i> , "Application of a human tumor colony-forming assay to new drug screening," <i>Cancer Res.</i> , 45:2145-2153, 1985.
	C204	Stremovskii <i>et al.</i> , "Functional construction of anti-ferritin mini-antibody/ribonuclease," <i>Medicinal Immunol.</i> , 3:279, 2001.
	C205	Suhrbier <i>et al.</i> , "Role of single amino acids in the recognition of a T cell epitope," <i>J. Immunol.</i> , 147:2507-2513, 1991.
	C206	Wild <i>et al.</i> , "Inhibition of angiogenesis and tumour growth by VEGF121-toxin conjugate: differential effect on proliferating endothelial cells," <i>Br. J. Cancer</i> , 83:1077-1083, 2000.
	C207	Yudina <i>et al.</i> , "Study of interaction between anti-HER-2/NEU-mini-antibodies with SKOV-3 ovarian adenocarcinoma cells," <i>Medicinal Immunol.</i> , 3:285, 2001.

25761645.1

EXAMINER: /Laura B. Goddard/	DATE CONSIDERED: 04/24/2008
------------------------------	-----------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPE609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.B.G./